Analysts Say Buy These Stocks: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Green Plains, Inc. (NASDAQ:GPRE), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), MediWound Ltd. (NASDAQ:MDWD)

Wall Street analysts are maintaining Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) company shares.  The one year target on the name currently stands at $44.80.  The stock recently touched $20.35 and has moved in the range of $20.24 - 23.30 during the current session.  Based on a recent bid this places the stock +22.30% away from the 52-week floor of $16.64 and -60.86% away from the 52-week ceiling of $51.99.

When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary.  Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth.  Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year.  Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.

Green Plains, Inc. (NASDAQ:GPRE) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $20.27 on the stock. The stock is currently trading -22.26% away from its 200-day moving average of $19.06. Based on a recent trade, shares of Green Plains, Inc. are -56.48% away from the 52-week high of $34.05 and +19.61% away from the 52-week low of $12.39.

Analysts are estimating that the company will report earnings of $0.47 for the current year and $-0.11 for next quarter. The stock closed the most recent trading session at $15.20.

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $28.600 price target and Buy rating according to the covering analysts.  During today’s session the stock hit $16.825 or -7.960% from the previous close, while moving in the range of $16.550 - 18.380.

Shares of MediWound Ltd. (NASDAQ:MDWD) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $15.00 price target according to the covering analysts.  During today’s session the stock hit $7.56 or +2.47% from the previous close, while moving in the range of $7.53 - 8.16.  This puts the stock -25.98% away from the 52-week high of $10.47 and +55.00% away from the 52-week low of $5.00.

Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm.  The consensus rating simply provides an average of those recommendations.  It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Add Comment